BAKER BROS. ADVISORS LP 13D and 13G filings for Kala Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-31 4:18 pm Purchase | 2024-12-29 | 13D | Kala Pharmaceuticals, Inc. KALA | BAKER BROS. ADVISORS LP | 1,201,894 19.700% | 310,559 (+34.84%) | Filing |
| 2024-06-28 4:11 pm Purchase | 2024-06-26 | 13D | Kala Pharmaceuticals, Inc. KALA | BAKER BROS. ADVISORS LP | 891,335 19.990% | 622,122 (+231.09%) | Filing |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA | BAKER BROS. ADVISORS LP | 269,213 9.990% | 88,300 (+48.81%) | Filing |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA | BAKER BROS. ADVISORS LP | 180,913 9.990% | 180,913 (New Position) | Filing |